Martyna Gołębiewska

Martyna Gołębiewska


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
DPDamian Krystian Palus
Damian Krystian Palus
MGMartyna Gołębiewska
Martyna Gołębiewska
OPOlga Piątek
Olga Piątek
KGKrzysztof Grudziński
Krzysztof Grudziński
AMAlan Majeranowski
Alan Majeranowski
TSTomasz Stefaniak
Tomasz Stefaniak
Objectives Presenting outcomes of patients hospitalised for COVID-19 should be put in context and comparison with other facilities. However, varied methodology applied in published studies can impede or even hinder a reliable comparison. The aim of this study is to share our experience in pandemic management and highlight previously under-reported factors affecting mortality. We present outcomes of COVID-19 treatment in our facility that will allow for an intercentre comparison. We use simple statistical parameters—case fatality ratio (CFR) and length of stay (LOS). Setting Large clinical hospital in northern Poland serving over 120 000 patients annually. Participants Data were collected from patients hospitalised in COVID-19 general and intensive care unit (ICU) isolation wards from November 2020 to June 2021. The sample consisted of 640 patients—250 (39.1 %) were women and 390 (60.9 %) were men, with a median age of 69 (IQR 59–78) years. Results Values of LOS and CFR were calculated and analysed. Overall CFR for the analysed period was 24.8%, varying from 15.9 % during second quarter 2021 to 34.1% during fourth quarter 2020. The CFR was 23.2% in the general ward and 70.7% in the ICU. All ICU patients required intubation and mechanical ventilation, and 44 (75.9 %) of them developed acute respiratory distress syndrome. The average LOS was 12.6 (±7.5) days. Conclusions We highlighted the importance of some of the under-reported factors affecting CFR, LOS and thus, mortality. For further multicentre analysis, we recommend broad analysis of factors affecting mortality in COVID-19 using simple and transparent statistical and clinical parameters.

1 January 2024 in European Psychiatry
Verified
Journal Article
Open access
PDF file
CTCristiana Tapoi
Cristiana Tapoi
LALaith Alexander
Laith Alexander
Renato de FilippisRenato de Filippis
Renato de Filippis
Agorastos AgorastosAgorastos Agorastos
Agorastos Agorastos
DADiogo Almeida
Diogo Almeida
MCMariana Pinto da Costa
Mariana Pinto da Costa
Background: Electroconvulsive therapy (ECT) is a safe and effective treatment for several major psychiatric conditions, including treatment-resistant depression, mania, and schizophrenia; nevertheless, its use remains controversial. Despite its availability in some European countries, ECT is still rarely used in others. This study aims to investigate the experiences and attitudes of early career psychiatrists (ECPs) across Europe towards ECT and to examine how their exposure to ECT influences their perceptions. Methods: In Europe, a cross-sectional survey was conducted among ECPs, including psychiatric trainees and recently fully qualified psychiatrists. Results: A total of 573 participants from 30 European countries were included in the study, of whom more than half (N = 312; 54.5%) received ECT training. Overall, ECPs had a positive attitude towards ECT, with the vast majority agreeing or strongly agreeing that ECT is an effective (N = 509; 88.8%) and safe (N = 464; 81.0%) treatment and disagreeing or strongly disagreeing that ECT was used as a form of control or punishment (N = 545; 95.1%). Those who had received ECT training during their psychiatry training were more likely to recommend ECT to their patients (p < 0.001, r = 0.34), and held more positive views on its safety (p < 0.001, r = 0.31) and effectiveness (p < 0.001, r = 0.33). Interest in further education about ECT was moderately high (modal rating on Likert scale: 4, agree), irrespective of prior training exposure. Conclusions: ECT training is associated with more favorable perceptions of its safety and effectiveness among ECPs. There is a general willingness among ECPs to expand their knowledge and training on ECT, which could enhance patients’ access to this treatment.

30 September 2022 in Palliative Medicine in Practice
Verified
Journal Article
Open access
PDF file
MGMartyna Gołębiewska
Martyna Gołębiewska
OPOlga Piątek
Olga Piątek
Krzysztof KuziemskiKrzysztof Kuziemski
Krzysztof Kuziemski
TSTomasz Stefaniak
Tomasz Stefaniak
The emergence of the coronavirus pandemic in 2020 has challenged many aspects of the management of clinical care. It has negatively impacted the already overwhelmed healthcare system in Poland, leading to further limitation of access to specialist care, delay of treatment and even failure to initiate it. Patients with severe, rapidly progressing diseases such as cancer, are among those most adversely affected. Immunocompromised patients are prone to persistent COVID-19 infection and re-test positively even when asymptomatic. In this case report, the authors present an immunocompromised patient with follicular lymphoma and active tuberculosis, who re-tested positive for SARS-CoV-2 in real-time polymerase chain reaction and rapid antigen tests twenty-two times over seventeen weeks of hospitalisation in the isolation ward in University Clinical Centre in Gdansk, Poland. The management of her oncological treatment was significantly disturbed by prolonged isolation and organisational issues arising from the coronavirus pandemic. The emergence of the coronavirus pandemic in 2020 has challenged many aspects of the management of clinical care. It has negatively impacted the already overwhelmed healthcare system in Poland, leading to further limitation of access to specialist care, delay of treatment and even failure to initiate it. Patients with severe, rapidly progressing diseases such as cancer, are among those most adversely affected. Immunocompromised patients are prone to persistent COVID-19 infection and re-test positively even when asymptomatic. In this case report, the authors present an immunocompromised patient with follicular lymphoma and active tuberculosis, who re-tested positive for SARS-CoV-2 in real-time polymerase chain reaction and rapid antigen tests twenty-two times over seventeen weeks of hospitalisation in the isolation ward in University Clinical Centre in Gdansk, Poland. The management of her oncological treatment was significantly disturbed by prolonged isolation and organisational issues arising from the coronavirus pandemic.

25 February 2025 in Cardiology Journal
Verified
Journal Article
Open access
PDF file
DPDamian Palus
Damian Palus
MGMartyna Gołębiewska
Martyna Gołębiewska
OPOlga Piątek-Dalewska
Olga Piątek-Dalewska
KGKrzysztof Grudziński
Krzysztof Grudziński
Krzysztof KuziemskiKrzysztof Kuziemski
Krzysztof Kuziemski
TSTomasz J Stefaniak
Tomasz J Stefaniak
Background: This study evaluates the impact of pre-existing comorbidities and in-hospital complications on COVID-19 mortality rates. Methods: A retrospective single-center study was conducted using electronic health records from 640 COVID-19 patients hospitalized at the University Clinical Centre in Gdansk, Poland, between November 2020 and May 2021. Patients were categorized based on disease severity into stable or ICU wards based on the disease severity. Data on demographics, comorbidities, complications, and treatments were collected and verified. Statistical analyses, including odds ratios (ORs) and confidence intervals (CIs), assessed mortality risk factors supported by python-based processing. Results: The mean patient age was 67 years (SD ± 15.89), comprising 39% females (n = 250) and 60.94% males (n = 390). Mortality risk was highest in patients aged 65 years and older (OR 3.00; 95% CI, 1.97–4.60). Among the pre-existing comorbidities, chronic kidney disease (OR 3.28; 95% CI, 2.12–5.09), atrial fibrillation (OR 2.43; CI 95%, 1.63–3.61), and heart failure (OR 2.89; 95% CI, 1.91–4.37) were significant predictors of mortality. In hospital complications, such as severe respiratory failure requiring ICU ventilation (OR 23.59; 95% CI, 2.81–197.87), myocardial infarction (OR 25.43; 95% CI, 3.16–204.97), acute kidney injury requiring renal replacement therapy (OR 19.15; 95% CI, 6.49–56.51), sepsis (OR 7.22, 95% CI, 3.77–13.84), stroke, further increased mortality risk. Conclusions: COVID-19 patients with pre-existing renal and cardiovascular conditions face a higher risk of fatal outcomes. Early diagnosis and intervention targeting these complications are vital to in reducing mortality. Further research is needed to reconcile disparities with existing literature. Keywords: COVID-19 complications SARS-CoV-2 comorbidity in-hospital mortality risk factors

12 December 2025 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
OPOlga Piątek-Dalewska
Olga Piątek-Dalewska
Krzysztof KuziemskiKrzysztof Kuziemski
Krzysztof Kuziemski
PGPeter Grešner
Peter Grešner
ZAZielińska Alicja
Zielińska Alicja
TSTomasz J Stefaniak
Tomasz J Stefaniak
DPDamian Palus
Damian Palus
Solid organ transplant recipients were among the most vulnerable groups during the COVID-19 pandemic. Chronic immunosuppression and multiple comorbidities

9 July 2022 in medRxiv
Verified
Preprint
Open access
PDF file
DPDamian Palus
Damian Palus
MGMartyna Gołębiewska
Martyna Gołębiewska
OPOlga Piątek-Dalewska
Olga Piątek-Dalewska
AMAlan Majeranowski
Alan Majeranowski
Radoslaw OwczukRadoslaw Owczuk
Radoslaw Owczuk
TSTomasz J Stefaniak
Tomasz J Stefaniak
Introduction: Presenting outcomes of patients hospitalised for coronavirus disease (COVID-19) should be put in context and comparison with other facilities. Number of statistical parameters can be used to compare effectiveness of treatment, however varied methodology applied in studies can impede or hinder a reliable comparison. The aim of this study is to present outcomes of COVID-19 treatment in our facility using simplest parameters allowing for intercenter comparison - case fatality ratio (CFR), length of stay (LOS) and transparent patients’ characteristics, and to discuss factors affecting mortality in COVID-19. Methods: The data were collected from patients hospitalized in COVID-19 general and ICU isolation wards in the University Clinical Centre (UCC) in Gdansk, Poland, from November 2020 to June 2021, using a computer-based patient record system. The group consisted of 642 patients – 144 (39,1 %) were women and 391 (60,9 %) were men, with a median age of 69 (IQR 59-78) years. Values of LOS and CFR were calculated and analysed. Results: Overall CFR for the analysed period was 24,8 %, varying from 19,9 % in January to May 2021 to 33,8 % in November to December 2020. CFR was 18,9 % in general ward and 70,7 % in ICU. All ICU patients required intubation and mechanical ventilation, and forty-four (75,9 %) of them developed acute respiratory distress syndrome (ARDS). Average length of stay was 13,1 (± 7,1) days. Conclusion: CFR in the general ward in UCC was analogous to published outcomes, but higher in our ICU ward. It resulted from more rigorous ICU admittance criteria in UCC compared to other facilities, which corresponds with patients’ severe clinical condition and unfavourable prognosis. Heterogeneity of methods assessing initial clinical condition in different facilities makes a meaningful intercenter comparison challenging. In this study, we propose simple and transparent statistical and clinical parameters applicable in an intercenter analysis. What is already known on this topic - the outbreak of global pandemic caused by novel coronavirus SARS-CoV-2 has strained healthcare systems all over the world. Healthcare workers faced new challenges, as organisational, structural, and personal flaws were unearthed in the process. In subsequent waves the number of hospitalisations increased together with the death number in the ICUs. As we come to terms with a new disease, numerous studies reports, analyse and assess COVID-19 treatment outcomes What this study adds - COVID-19 treatment outcomes in ICU in our facility contrast with most of the published reports. We analyse the influence of some commonly omitted under-examined factors and propose simple and applicable parameters to compare results, such as CFR and LOS, enabling a meaningful intercenter comparison. How this study might affect research, practice, or policy - inclusion of CFR and LOS in studies on COVID-19 would remove significant bias and enable more robust evaluation of therapeutic interventions and outcomes. In this study we also discuss heterogeneity of admission criteria and show how their influence on treatment outcomes.